News

Alembic Pharma soars on getting USFDA approval for Diltiazem Hydrochloride Extended-Release Capsules Alembic Pharmaceuticals is currently trading at Rs. 1177.95, up by 18.20 points or 1.57% from its previous closing of Rs. 1159.75 on the BSE. The scrip opened at Rs. 1160.05 and has touched a high and low of Rs. 1186.00 and Rs. 1160.05 respectively. So far 1003 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1296.15 on 09-Oct-2024 and a 52 week low of Rs. 707.50 on 31-Oct-2023. Last one week high and low of the ...
Alembic Pharma soars on getting USFDA approval for Diltiazem Hydrochloride Extended-Release Capsules
Alembic Pharma soars on getting USFDA approval for Diltiazem Hydrochloride Extended-Release Capsules
Source: Accord Fintech
2024-10-21 09:57:40 am
Zydus Lifesciences gains on getting USFDA`s final approval for Paliperidone Extended-Release Tablets Zydus Lifesciences is currently trading at Rs. 1062.75, up by 5.75 points or 0.54% from its previous closing of Rs. 1057.00 on the BSE. The scrip opened at Rs. 1062.00 and has touched a high and low of Rs. 1064.15 and Rs. 1052.00 respectively. So far 67192 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1323.90 on 09-Aug-2024 and a 52 week low of Rs. 567.85 on 26-Oct-2023. Last one week high and low of the scrip...
Zydus Lifesciences gains on getting USFDA`s final approval for Paliperidone Extended-Release Tablets
Zydus Lifesciences gains on getting USFDA`s final approval for Paliperidone Extended-Release Tablets
Source: Accord Fintech
2024-10-11 12:50:42 pm
Alembic Pharmaceuticals inches up on getting final nod for Alcaftadine Ophthalmic Solution Alembic Pharmaceuticals is currently trading at Rs. 1245.00, up by 2.85 points or 0.23% from its previous closing of Rs. 1242.15 on the BSE. The scrip opened at Rs. 1259.65 and has touched a high and low of Rs. 1259.65 and Rs. 1217.05 respectively. So far 6937 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1285.60 on 08-Aug-2024 and a 52 week low of Rs. 707.50 on 31-Oct-2023. Last one week high and low of the s...
Alembic Pharmaceuticals inches up on getting final nod for Alcaftadine Ophthalmic Solution
Alembic Pharmaceuticals inches up on getting final nod for Alcaftadine Ophthalmic Solution
Source: Accord Fintech
2024-10-04 10:14:58 am
Aurobindo Pharma rises on getting USFDA`s final approval for Cephalexin Tablets Aurobindo Pharma is currently trading at Rs. 1452.90, up by 14.35 points or 1.00% from its previous closing of Rs. 1438.55 on the BSE. The scrip opened at Rs. 1438.55 and has touched a high and low of Rs. 1459.75 and Rs. 1425.05 respectively. So far 20028 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1592.55 on 13-Sep-2024 and a 52 week low of Rs. 834.90 on 01-Nov-2023. Last one week high and low of the scrip ...
Aurobindo Pharma rises on getting USFDA`s final approval for Cephalexin Tablets
Aurobindo Pharma rises on getting USFDA`s final approval for Cephalexin Tablets
Source: Accord Fintech
2024-10-03 01:36:20 pm
Alembic Pharmaceuticals surges on getting USFDA`s final approval for Lamotrigine Extended-Release Tablets Alembic Pharmaceuticals is currently trading at Rs. 1220.90, up by 30.45 points or 2.56% from its previous closing of Rs. 1190.45 on the BSE. The scrip opened at Rs. 1185.00 and has touched a high and low of Rs. 1222.85 and Rs. 1169.70 respectively. So far 978 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1285.60 on 08-Aug-2024 and a 52 week low of Rs. 707.50 on 31-Oct-2023. Last one week high and low of the s...
Alembic Pharmaceuticals surges on getting USFDA`s final approval for Lamotrigine Extended-Release Tablets
Alembic Pharmaceuticals surges on getting USFDA`s final approval for Lamotrigine Extended-Release Tablets
Source: Accord Fintech
2024-10-03 09:51:43 am
Alembic Pharmaceuticals surges after getting EIR from USFDA for Oral Solid Formulation Facility Alembic Pharmaceuticals is currently trading at Rs. 1205.45, up by 12.80 points or 1.07% from its previous closing of Rs. 1192.65 on the BSE. The scrip opened at Rs. 1204.95 and has touched a high and low of Rs. 1248.95 and Rs. 1184.75 respectively. So far 28472 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1285.60 on 08-Aug-2024 and a 52 week low of Rs. 707.50 on 31-Oct-2023. Last one week high and low of the...
Alembic Pharmaceuticals surges after getting EIR from USFDA for Oral Solid Formulation Facility
Alembic Pharmaceuticals surges after getting EIR from USFDA for Oral Solid Formulation Facility
Source: Accord Fintech
2024-09-30 04:17:32 pm
Biocon falls after USFDA completes surveillance inspection at its API facility with four observations Biocon is currently trading at Rs. 363.55, down by 5.15 points or 1.40% from its previous closing of Rs. 368.70 on the BSE. The scrip opened at Rs. 366.85 and has touched a high and low of Rs. 369.00 and Rs. 361.50 respectively. So far 151349 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 395.65 on 17-Sep-2024 and a 52 week low of Rs. 217.50 on 31-Oct-2023. Last one week high and low of the scrip stood at Rs. 3...
Biocon falls after USFDA completes surveillance inspection at its API facility with four observations
Biocon falls after USFDA completes surveillance inspection at its API facility with four observations
Source: Accord Fintech
2024-09-30 02:51:32 pm
Saksoft, HDFC Life and Tata Motors to see some action today Saksoft has acquired Ceptes Software, a recognized expert in Salesforce services, headquartered in Bengaluru, Karnataka. The company anticipates the transaction will be closed within 4 weeks pending customary closing conditions. This strategic acquisition will significantly help Saksoft expand its capabilities around Salesforce solutions, cloud innovation, and customer experience optimization.  HDFC Life Insurance Company has received approval to raise funds up to Rs 1,500 c...
Saksoft, HDFC Life and Tata Motors to see some action today
Saksoft, HDFC Life and Tata Motors to see some action today
Source: Accord Fintech
2024-09-30 08:57:05 am
Strides Pharma Science surges as its arm gets USFDA`s approval for Theophylline Extended-Release Tablets Strides Pharma Science is currently trading at Rs. 1377.50, up by 33.50 points or 2.49% from its previous closing of Rs. 1344.00 on the BSE. The scrip opened at Rs. 1354.90 and has touched a high and low of Rs. 1394.95 and Rs. 1347.60 respectively. So far 6016 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1,394.95  on 06-Sep-2024 and a 52 week low of Rs. 452.75 on 12-Sep-2023. Last one week high and low ...
Strides Pharma Science surges as its arm gets USFDA`s approval for Theophylline Extended-Release Tablets
Strides Pharma Science surges as its arm gets USFDA`s approval for Theophylline Extended-Release Tablets
Source: Accord Fintech
2024-09-06 11:54:12 am
Lupin zooms on launching Mirabegron Extended-Release Tablets in United States Lupin is currently trading at Rs. 2274.10, up by 35.00 points or 1.56% from its previous closing of Rs. 2239.10 on the BSE. The scrip opened at Rs. 2220.75 and has touched a high and low of Rs. 2286.25 and Rs. 2205.25 respectively. So far 17884 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2,286.25 on 04-Sep-2024 and a 52 week low of Rs. 1091.80 on 22-Sep-2023. Last one week high and low of the scrip stood at ...
Lupin zooms on launching Mirabegron Extended-Release Tablets in United States
Lupin zooms on launching Mirabegron Extended-Release Tablets in United States
Source: Accord Fintech
2024-09-04 04:35:55 pm
Biocon rises as its arm secures approval from USFDA for Sacubitril/Valsartan Tablets Biocon is currently trading at Rs. 361.45, up by 2.15 points or 0.60% from its previous closing of Rs. 359.30 on the BSE. The scrip opened at Rs. 367.50 and has touched a high and low of Rs. 368.00 and Rs. 359.00 respectively. So far 130805 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 376.75 on 26-Jul-2024 and a 52 week low of Rs. 217.50 on 31-Oct-2023. Last one week high and low of the scrip stood at Rs. 368...
Biocon rises as its arm secures approval from USFDA for Sacubitril/Valsartan Tablets
Biocon rises as its arm secures approval from USFDA for Sacubitril/Valsartan Tablets
Source: Accord Fintech
2024-09-02 11:18:40 am
Zydus Lifesciences gains on getting USFDA’s final approval for Scopolamine Transdermal System Zydus Lifesciences gains on getting USFDA’s final approval for Scopolamine Transdermal System Aug-30-2024   14:08 Hrs IST Zydus Lifesciences is currently trading at Rs. 1145.55, up by 13.30 points or 1.17% from its previous closing of Rs. 1132.25 on the BSE. The scrip opened at Rs. 1140.00 and has touched a high and low of Rs. 1159.00 and Rs. 1128.95 respectively. So far 155881 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 h...
Zydus Lifesciences gains on getting USFDA’s final approval for Scopolamine Transdermal System
Zydus Lifesciences gains on getting USFDA’s final approval for Scopolamine Transdermal System
Source: Accord Fintech
2024-08-30 02:28:43 pm
Zydus Lifesciences surges on getting final nod to market Amantadine extended-release capsules Zydus Lifesciences is currently trading at Rs. 1134.20, up by 20.35 points or 1.83% from its previous closing of Rs. 1113.85 on the BSE. The scrip opened at Rs. 1147.05 and has touched a high and low of Rs. 1156.45 and Rs. 1128.05 respectively. So far 38036 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1323.90 on 09-Aug-2024 and a 52 week low of Rs. 567.85 on 26-Oct-2023. Last one week high and low of the scri...
Zydus Lifesciences surges on getting final nod to market Amantadine extended-release capsules
Zydus Lifesciences surges on getting final nod to market Amantadine extended-release capsules
Source: Accord Fintech
2024-08-28 09:46:10 am
Shilpa Medicare zooms on securing USFDA’s approval for Bortezomib Injection Shilpa Medicare is currently trading at Rs. 760.75, up by 28.15 points or 3.84% from its previous closing of Rs. 732.60 on the BSE. The scrip opened at Rs. 743.05 and has touched a high and low of Rs. 798.00 and Rs. 741.75 respectively. So far 122239 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 798.00 on 27-Aug-2024 and a 52 week low of Rs. 296.45 on 26-Oct-2023. Last one week high and low of the scrip stood ...
Shilpa Medicare zooms on securing USFDA’s approval for Bortezomib Injection
Shilpa Medicare zooms on securing USFDA’s approval for Bortezomib Injection
Source: Accord Fintech
2024-08-27 03:27:40 pm
Alembic Pharmaceuticals gains on getting USFDA`s final approval for Betamethasone Valerate Foam Alembic Pharmaceuticals is currently trading at Rs. 1112.85, up by 12.30 points or 1.12% from its previous closing of Rs. 1100.55 on the BSE. The scrip opened at Rs. 1227.35 and has touched a high and low of Rs. 1227.35 and Rs. 1107.05 respectively. So far 15526 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1285.60 on 08-Aug-2024 and a 52 week low of Rs. 707.50 on 31-Oct-2023. Last one week high and low of the...
Alembic Pharmaceuticals gains on getting USFDA`s final approval for Betamethasone Valerate Foam
Alembic Pharmaceuticals gains on getting USFDA`s final approval for Betamethasone Valerate Foam
Source: Accord Fintech
2024-08-26 12:21:56 pm
Wanbury shines on getting EIR from USFDA for Maharashtra manufacturing facility Wanbury is currently trading at Rs. 218.20, up by 8.20 points or 3.90% from its previous closing of Rs. 210.00 on the BSE. The scrip opened at Rs. 213.60 and has touched a high and low of Rs. 220.50 and Rs. 213.00 respectively. So far 66631 shares were traded on the counter. The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 223.00 on 29-Jul-2024 and a 52 week low of Rs. 51.40 on 28-Aug-2023. Last one week high and low of the scrip stood at Rs. 220...
Wanbury shines on getting EIR from USFDA for Maharashtra manufacturing facility
Wanbury shines on getting EIR from USFDA for Maharashtra manufacturing facility
Source: Accord Fintech
2024-08-23 03:47:02 pm
Indoco Remedies climbs on getting USFDA’s final approval for Lofexidine Tablets Indoco Remedies is currently trading at Rs. 351.05, up by 15.65 points or 4.67% from its previous closing of Rs. 335.40 on the BSE. The scrip opened at Rs. 336.55 and has touched a high and low of Rs. 353.95 and Rs. 336.55 respectively. So far 29140 shares were traded on the counter. The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 416.95 on 01-Jan-2024 and a 52 week low of Rs. 286.50 on 04-Jun-2024. Last one week high and low of the scrip stood a...
Indoco Remedies climbs on getting USFDA’s final approval for Lofexidine Tablets
Indoco Remedies climbs on getting USFDA’s final approval for Lofexidine Tablets
Source: Accord Fintech
2024-08-21 03:58:00 pm
Marksans Pharma soars after its arm secures marketing authorization for three products Marksans Pharma is currently trading at Rs. 223.30, up by 2.40 points or 1.09% from its previous closing of Rs. 220.90 on the BSE. The scrip opened at Rs. 220.05 and has touched a high and low of Rs. 224.95 and Rs. 218.45 respectively. So far 180885 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 224.95 on 21-Aug-2024 and a 52 week low of Rs. 93.85 on 18-Sep-2023. Last one week high and low of the scrip stood at...
Marksans Pharma soars after its arm secures marketing authorization for three products
Marksans Pharma soars after its arm secures marketing authorization for three products
Source: Accord Fintech
2024-08-21 12:32:55 pm
Aurobindo Pharma surges on securing USFDA’s approval for Estradiol Vaginal Inserts Aurobindo Pharma is currently trading at Rs. 1479.40, up by 15.30 points or 1.05% from its previous closing of Rs. 1464.10 on the BSE. The scrip opened at Rs. 1477.75 and has touched a high and low of Rs. 1480.40 and Rs. 1448.85 respectively. So far 8770 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1480.40 on 08-Aug-2024 and a 52 week low of Rs. 815.15 on 05-Sep-2023. Last one week high and low of the scrip s...
Aurobindo Pharma surges on securing USFDA’s approval for Estradiol Vaginal Inserts
Aurobindo Pharma surges on securing USFDA’s approval for Estradiol Vaginal Inserts
Source: Accord Fintech
2024-08-08 03:27:18 pm
Gland Pharma falls after USFDA concludes inspection at Pashamylaram Facility with three observations Gland Pharma is currently trading at Rs. 2123.05, down by 4.75 points or 0.22% from its previous closing of Rs. 2127.80 on the BSE. The scrip opened at Rs. 2000.05 and has touched a high and low of Rs. 2149.35 and Rs. 2000.05 respectively. So far 31509 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2195.75 on 07-Feb-2024 and a 52 week low of Rs. 1,303.15 on 07-Aug-2023. Last one week high and low of the scrip s...
Gland Pharma falls after USFDA concludes inspection at Pashamylaram Facility with three observations
Gland Pharma falls after USFDA concludes inspection at Pashamylaram Facility with three observations
Source: Accord Fintech
2024-08-05 02:54:40 pm
Alembic Pharmaceuticals gains on securing USFDA’s final approval for Nelarabine Injection Alembic Pharmaceuticals gains on securing USFDA’s final approval for Nelarabine Injection Aug-02-2024   12:16 Hrs IST Alembic Pharmaceuticals is currently trading at Rs. 1220.05, up by 4.45 points or 0.37% from its previous closing of Rs. 1215.60 on the BSE. The scrip opened at Rs. 1215.45 and has touched a high and low of Rs. 1231.25 and Rs. 1190.85 respectively. So far 9174 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has...
Alembic Pharmaceuticals gains on securing USFDA’s final approval for Nelarabine Injection
Alembic Pharmaceuticals gains on securing USFDA’s final approval for Nelarabine Injection
Source: Accord Fintech
2024-08-02 12:25:59 pm
Sun Pharmaceutical climbs on getting USFDA’s nod for LEQSELVI tablets Sun Pharmaceutical Industries is currently trading at Rs. 1704.80, up by 39.60 points or 2.38% from its previous closing of Rs. 1665.20 on the BSE. The scrip opened at Rs. 1675.00 and has touched a high and low of Rs. 1712.00 and Rs. 1665.20 respectively. So far 103105 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1,712.00 on 26-Jul-2024 and a 52 week low of Rs. 1069.00 on 31-Oct-2023. Last one week high and l...
Sun Pharmaceutical climbs on getting USFDA’s nod for LEQSELVI tablets
Sun Pharmaceutical climbs on getting USFDA’s nod for LEQSELVI tablets
Source: Accord Fintech
2024-07-26 03:04:23 pm
Zydus Lifesciences falls after USFDA classifies its`Jarod unit as `official action indicated` Zydus Lifesciences is currently trading at Rs. 1160.15, down by 25.15 points or 2.12% from its previous closing of Rs. 1185.30 on the BSE. The scrip opened at Rs. 1165.00 and has touched a high and low of Rs. 1168.75 and Rs. 1151.00 respectively. So far 89918 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1203.20 on 11-Jul-2024 and a 52 week low of Rs. 564.05 on 25-Jul-2023. Last one week high and low of the sc...
Zydus Lifesciences falls after USFDA classifies its`Jarod unit as `official action indicated`
Zydus Lifesciences falls after USFDA classifies its`Jarod unit as `official action indicated`
Source: Accord Fintech
2024-07-19 12:28:26 pm
Zydus Lifesciences inches up on getting USFDA`s final approval for Sacubitril and Valsartan Tablets Zydus Lifesciences is currently trading at Rs. 1181.15, up by 0.75 points or 0.06% from its previous closing of Rs. 1180.40 on the BSE. The scrip opened at Rs. 1199.45 and has touched a high and low of Rs. 1203.20 and Rs. 1176.35 respectively. So far 26907 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1,203.20 on 11-Jul-2024 and a 52 week low of Rs. 564.05 on 25-Jul-2023. Last one week high and low of the scri...
Zydus Lifesciences inches up on getting USFDA`s final approval for Sacubitril and Valsartan Tablets
Zydus Lifesciences inches up on getting USFDA`s final approval for Sacubitril and Valsartan Tablets
Source: Accord Fintech
2024-07-11 11:38:54 am
Alembic Pharma gains on getting USFDA`s final approval for Bromfenac Ophthalmic Solution Alembic Pharmaceuticals is currently trading at Rs. 978.70, up by 4.80 points or 0.49% from its previous closing of Rs. 973.90 on the BSE. The scrip opened at Rs. 985.00 and has touched a high and low of Rs. 1005.10 and Rs. 964.85 respectively. So far 12484 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1093.05 on 21-Feb-2024 and a 52 week low of Rs. 641.65 on 14-Jul-2023. Last one week high and low of the scri...
Alembic Pharma gains on getting USFDA`s final approval for Bromfenac Ophthalmic Solution
Alembic Pharma gains on getting USFDA`s final approval for Bromfenac Ophthalmic Solution
Source: Accord Fintech
2024-07-10 02:37:53 pm
Alembic Pharma shines on getting USFDA`s tentative approval for Ivosidenib Tablets Alembic Pharmaceuticals is currently trading at Rs. 988.80, up by 38.80 points or 4.08% from its previous closing of Rs. 950.00 on the BSE. The scrip opened at Rs. 970.00 and has touched a high and low of Rs. 990.00 and Rs. 955.10 respectively. So far 6489 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1093.05 on 21-Feb-2024 and a 52 week low of Rs. 635.00 on 05-Jul-2023. Last one week high and low of the scrip...
Alembic Pharma shines on getting USFDA`s tentative approval for Ivosidenib Tablets
Alembic Pharma shines on getting USFDA`s tentative approval for Ivosidenib Tablets
Source: Accord Fintech
2024-07-04 02:30:29 pm
Sun Pharmaceutical Industries declines on getting warning letter from USFDA for Dadra facility Sun Pharmaceutical Industries is currently trading at Rs. 1481.00, down by 23.15 points or 1.54% from its previous closing of Rs. 1504.15 on the BSE. The scrip opened at Rs. 1489.95 and has touched a high and low of Rs. 1489.95 and Rs. 1475.55 respectively. So far 26550 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1638.70 on 05-Apr-2024 and a 52 week low of Rs. 977.50 on 23-Jun-2023. Last one week high and lo...
Sun Pharmaceutical Industries declines on getting warning letter from USFDA for Dadra facility
Sun Pharmaceutical Industries declines on getting warning letter from USFDA for Dadra facility
Source: Accord Fintech
2024-06-20 11:06:35 am
Alembic Pharma gains on getting USFDA`s final nod for Icatibant Injection Alembic Pharmaceuticals is currently trading at Rs. 894.90, up by 4.80 points or 0.54% from its previous closing of Rs. 890.10 on the BSE. The scrip opened at Rs. 905.00 and has touched a high and low of Rs. 917.50 and Rs. 891.75 respectively. So far 2464 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1093.05 on 21-Feb-2024 and a 52 week low of Rs. 600.65 on 23-Jun-2023. Last one week high and low of the scrip ...
Alembic Pharma gains on getting USFDA`s final nod for Icatibant Injection
Alembic Pharma gains on getting USFDA`s final nod for Icatibant Injection
Source: Accord Fintech
2024-06-18 10:46:07 am
Zydus Lifesciences jumps on getting USFDA`s tentative nod for Azilsartan Medoxomil and Chlorthalidone Tablets Zydus Lifesciences is currently trading at Rs. 1103.45, up by 13.15 points or 1.21% from its previous closing of Rs. 1090.30 on the BSE. The scrip opened at Rs. 1095.20 and has touched a high and low of Rs. 1109.70 and Rs. 1093.80 respectively. So far 112109 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1171.95 on 21-May-2024 and a 52 week low of Rs. 533.10 on 15-Jun-2023. Last one week high and low of the scr...
Zydus Lifesciences jumps on getting USFDA`s tentative nod for Azilsartan Medoxomil and Chlorthalidone Tablets
Zydus Lifesciences jumps on getting USFDA`s tentative nod for Azilsartan Medoxomil and Chlorthalidone Tablets
Source: Accord Fintech
2024-06-14 03:53:41 pm
Alembic Pharma jumps on getting USFDA`s final nod for Sacubitril and Valsartan tablets Alembic Pharmaceuticals is currently trading at Rs. 959.35, up by 16.85 points or 1.79% from its previous closing of Rs. 942.50 on the BSE. The scrip opened at Rs. 942.50 and has touched a high and low of Rs. 960.00 and Rs. 936.70 respectively. So far 3793 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1093.05 on 21-Feb-2024 and a 52 week low of Rs. 542.40 on 31-May-2023. Last one week high and low of the scrip...
Alembic Pharma jumps on getting USFDA`s final nod for Sacubitril and Valsartan tablets
Alembic Pharma jumps on getting USFDA`s final nod for Sacubitril and Valsartan tablets
Source: Accord Fintech
2024-05-31 04:04:29 pm
Cipla rises on getting USFDA’s final nod for Lanreotide injection Cipla is currently trading at Rs. 1457.80, up by 14.60 points or 1.01% from its previous closing of Rs. 1443.20 on the BSE. The scrip opened at Rs. 1451.10 and has touched a high and low of Rs. 1467.10 and Rs. 1437.10 respectively. So far 71397 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1519.00 on 11-Mar-2024 and a 52 week low of Rs. 915.50 on 22-May-2023. Last one week high and low of the scrip stood at Rs...
Cipla rises on getting USFDA’s final nod for Lanreotide injection
Cipla rises on getting USFDA’s final nod for Lanreotide injection
Source: Accord Fintech
2024-05-22 12:58:20 pm
Strides Pharma Science soars as its step-down arm gets USFDA’s approval for Sucralfate Oral Suspension Strides Pharma Science is currently trading at Rs. 854.90, up by 8.75 points or 1.03% from its previous closing of Rs. 846.15 on the BSE. The scrip opened at Rs. 846.75 and has touched a high and low of Rs. 856.30 and Rs. 841.25 respectively. So far 4887 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 914.00 on 06-May-2024 and a 52 week low of Rs. 346.40 on 25-May-2023. Last one week high and low of the scrip s...
Strides Pharma Science soars as its step-down arm gets USFDA’s approval for Sucralfate Oral Suspension
Strides Pharma Science soars as its step-down arm gets USFDA’s approval for Sucralfate Oral Suspension
Source: Accord Fintech
2024-05-22 11:40:26 am
Glenmark inches up on getting USFDA`s final approval for Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution Glenmark Pharmaceuticals is currently trading at Rs. 1009.80, up by 3.65 points or 0.36% from its previous closing of Rs. 1006.15 on the BSE. The scrip opened at Rs. 1006.20 and has touched a high and low of Rs. 1020.45 and Rs. 1005.70 respectively. So far 678 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1098.00 on 29-Apr-2024 and a 52 week low of Rs. 581.20 on 22-May-2023. Last one week high and low of the s...
Glenmark inches up on getting USFDA`s final approval for Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution
Glenmark inches up on getting USFDA`s final approval for Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution
Source: Accord Fintech
2024-05-17 10:41:11 am
Aurobindo Pharma trades in green on BSE Aurobindo Pharma is currently trading at Rs. 1145.20, up by 16.55 points or 1.47% from its previous closing of Rs. 1128.65 on the BSE. The scrip opened at Rs. 1126.40 and has touched a high and low of Rs. 1146.95 and Rs. 1118.60 respectively. So far 6564 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1177.00 on 30-Jan-2024 and a 52 week low of Rs. 581.50 on 19-May-2023. Last one week high and low of the scrip s...
Aurobindo Pharma trades in green on BSE
Aurobindo Pharma trades in green on BSE
Source: Accord Fintech
2024-05-13 10:59:36 am
Strides Pharma Science gains as its arm gets USFDA`s approval for Sevelamer Carbonate Tablets Strides Pharma Science is currently trading at Rs. 848.80, up by 17.35 points or 2.09 % from its previous closing of Rs. 831.45 on the BSE. The scrip opened at Rs. 840.95 and has touched a high and low of Rs. 858.10 and Rs. 812.35 respectively. So far 17766 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 914.00 on 06-May-2024 and a 52 week low of Rs. 346.40 on 25-May-2023. Last one week high and low of the scri...
Strides Pharma Science gains as its arm gets USFDA`s approval for Sevelamer Carbonate Tablets
Strides Pharma Science gains as its arm gets USFDA`s approval for Sevelamer Carbonate Tablets
Source: Accord Fintech
2024-05-10 04:11:55 pm
Gland Pharma gains on getting USFDA`s approval for Edaravone Injection Gland Pharma is currently trading at Rs. 1709.90, up by 3.30 points or 0.19% from its previous closing of Rs. 1706.60 on the BSE. The scrip opened at Rs. 1695.05 and has touched a high and low of Rs. 1723.25 and Rs. 1690.00 respectively. So far 2208 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2195.75 on 07-Feb-2024 and a 52 week low of Rs. 861.50 on 22-May-2023. Last one week high and low of the scrip stood ...
Gland Pharma gains on getting USFDA`s approval for Edaravone Injection
Gland Pharma gains on getting USFDA`s approval for Edaravone Injection
Source: Accord Fintech
2024-05-08 04:22:43 pm
Granules India gains as its arm gets USFDA`s approval for Colchicine Capsules Granules India is currently trading at Rs. 426.25, up by 6.05 points or 1.44% from its previous closing of Rs. 420.20 on the BSE. The scrip opened at Rs. 420.55 and has touched a high and low of Rs. 426.35 and Rs. 420.55 respectively. So far 7080 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 480.50 on 26-Feb-2024 and a 52 week low of Rs. 272.00 on 25-May-2023. Last one week high and low of the scrip stood at R...
Granules India gains as its arm gets USFDA`s approval for Colchicine Capsules
Granules India gains as its arm gets USFDA`s approval for Colchicine Capsules
Source: Accord Fintech
2024-04-30 11:31:42 am
Krishna Ella new President of Indian Vaccine Manufacturers' Association The Indian Vaccine Manufacturers Association (IVMA) on Monday announced Bharat Biotech Co-Founder and Executive Chairman Dr. Krishna M Ella will be its new President for a two-year period. A distinguished scientist and successful entrepreneur, Dr. Ella is acknowledged as the father of Genome Valley and is known for his pioneering work in biotechnology with his visionary leadership in the biotech industry. He takes over the Presidency from Adar C. Poonawala who held the post from 2019 to...
Krishna Ella new President of Indian Vaccine Manufacturers' Association
Krishna Ella new President of Indian Vaccine Manufacturers' Association
Source: IANS
2024-04-30 09:37:52 am
Glenmark Pharmaceuticals moves up on getting USFDA`s final approval for Acetaminophen and Ibuprofen Tablets Glenmark Pharmaceuticals is currently trading at Rs. 1088.25, up by 8.20 points or 0.76% from its previous closing of Rs. 1080.05 on the BSE. The scrip opened at Rs. 1092.60 and has touched a high and low of Rs. 1092.60 and Rs. 1085.60 respectively. So far 578 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1095.95 on 25-Apr-2024 and a 52 week low of Rs. 535.15 on 3-May-2023. Last one week high and low of the sc...
Glenmark Pharmaceuticals moves up on getting USFDA`s final approval for Acetaminophen and Ibuprofen Tablets
Glenmark Pharmaceuticals moves up on getting USFDA`s final approval for Acetaminophen and Ibuprofen Tablets
Source: Accord Fintech
2024-04-29 09:48:46 am
Lupin jumps on launching Mirabegron Extended-Release tablets Lupin is currently trading at Rs. 1594.85, up by 47.80 points or 3.09% from its previous closing of Rs. 1547.05 on the BSE. The scrip opened at Rs. 1599.50 and has touched a high and low of Rs. 1603.00 and Rs. 1570.35 respectively. So far 14575 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1703.80 on 11-Mar-2024 and a 52 week low of Rs. 678.90 on 20-Apr-2023. Last one week high and low of the scrip stood at Rs...
Lupin jumps on launching Mirabegron Extended-Release tablets
Lupin jumps on launching Mirabegron Extended-Release tablets
Source: Accord Fintech
2024-04-22 10:34:56 am
Strides Pharma Science gains as its arm gets USFDA`s approval for Fluoxetine Tabs Strides Pharma Science is currently trading at Rs. 842.10, up by 4.20 points or 0.50% from its previous closing of Rs. 837.90 on the BSE. The scrip opened at Rs. 847.85 and has touched a high and low of Rs. 850.75 and Rs. 839.75 respectively. So far 3229 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 860.00 on 09-Apr-2024 and a 52 week low of Rs. 304.85 on 11-Apr-2023. Last one week high and low of the scrip s...
Strides Pharma Science gains as its arm gets USFDA`s approval for Fluoxetine Tabs
Strides Pharma Science gains as its arm gets USFDA`s approval for Fluoxetine Tabs
Source: Accord Fintech
2024-04-10 03:22:27 pm
Alembic Pharma rises on getting tentative USFDA`s nod for breast cancer drug Alembic Pharmaceuticals is currently trading at Rs. 1013.55, up by 8.70 points or 0.87% from its previous closing of Rs. 1004.85 on the BSE. The scrip opened at Rs. 1008.95 and has touched a high and low of Rs. 1035.00 and Rs. 1003.80 respectively. So far 3128 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1093.05 on 21-Feb-2024 and a 52 week low of Rs. 485.05 on 05-Apr-2023. Last one week high and low of the s...
Alembic Pharma rises on getting tentative USFDA`s nod for breast cancer drug
Alembic Pharma rises on getting tentative USFDA`s nod for breast cancer drug
Source: Accord Fintech
2024-04-02 11:06:13 am
Caplin Point Laboratories gains as its arm gets USFDA approval for Ketorolac tromethamine Ophthalmic Solution Caplin Point Laboratories is currently trading at Rs. 1283.80, up by 23.85 points or 1.89 % from its previous closing of Rs. 1259.95 on the BSE. The scrip opened at Rs. 1289.90 and has touched a high and low of Rs. 1302.35 and Rs. 1259.45 respectively. So far 4701 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1617.80 on 19-Feb-2024 and a 52 week low of Rs. 575.00 on 29-Mar-2023. Last one week high and low of t...
Caplin Point Laboratories gains as its arm gets USFDA approval for Ketorolac tromethamine Ophthalmic Solution
Caplin Point Laboratories gains as its arm gets USFDA approval for Ketorolac tromethamine Ophthalmic Solution
Source: Accord Fintech
2024-03-28 12:07:12 pm
Zydus Lifesciences climbs on getting USFDA`s tentative approval for Letermovir Tablets Zydus Lifesciences is currently trading at Rs. 1020.35, up by 20.85 points or 2.09% from its previous closing of Rs. 999.50 on the BSE. The scrip opened at Rs. 1009.70 and has touched a high and low of Rs. 1028.45 and Rs. 995.15 respectively. So far 62307 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1028.45 on 26-Mar-2024 and a 52 week low of Rs. 471.10 on 27-Mar-2023. Last one week high and low of the scrip ...
Zydus Lifesciences climbs on getting USFDA`s tentative approval for Letermovir Tablets
Zydus Lifesciences climbs on getting USFDA`s tentative approval for Letermovir Tablets
Source: Accord Fintech
2024-03-26 03:39:03 pm
Aurobindo Pharma rises on getting final nod to manufacture, market Mometasone Furoate Monohydrate Nasal Spray Aurobindo Pharma is currently trading at Rs. 1004.05, up by 14.65 points or 1.48% from its previous closing of Rs. 989.40 on the BSE. The scrip opened at Rs. 1006.45 and has touched a high and low of Rs. 1013.90 and Rs. 996.00 respectively. So far 8516 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1177.00 on 30-Jan-2024 and a 52 week low of Rs. 466.00 on 21-Mar-2023. Last one week high and low of the scrip sto...
Aurobindo Pharma rises on getting final nod to manufacture, market Mometasone Furoate Monohydrate Nasal Spray
Aurobindo Pharma rises on getting final nod to manufacture, market Mometasone Furoate Monohydrate Nasal Spray
Source: Accord Fintech
2024-03-20 10:49:37 am
Zydus Lifesciences jumps on getting USFDA`s final approval for Chlorpromazine Hydrochloride Injection, Single-Dose Vials Zydus Lifesciences is currently trading at Rs. 990.40, up by 21.70 points or 2.24% from its previous closing of Rs. 968.70 on the BSE. The scrip opened at Rs. 969.05 and has touched a high and low of Rs. 999.70 and Rs. 961.85 respectively. So far 35265 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1015.70 on 11-Mar-2024 and a 52 week low of Rs. 463.20 on 14-Mar-2023. Last one week high and low of the scrip sto...
Zydus Lifesciences jumps on getting USFDA`s final approval for Chlorpromazine Hydrochloride Injection, Single-Dose Vials
Zydus Lifesciences jumps on getting USFDA`s final approval for Chlorpromazine Hydrochloride Injection, Single-Dose Vials
Source: Accord Fintech
2024-03-14 02:33:48 pm
Sun Pharma trades higher on the BSE Sun Pharmaceutical Industries is currently trading at Rs. 1619.60, up by 12.95 points or 0.81% from its previous closing of Rs. 1606.65 on the BSE. The scrip opened at Rs. 1608.45 and has touched a high and low of Rs. 1627.00 and Rs. 1600.00 respectively. So far 193787 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1,627.00 on 11-Mar-2024 and a 52 week low of Rs. 922.55 on 22-May-2023. Last one week high and lo...
Sun Pharma trades higher on the BSE
Sun Pharma trades higher on the BSE
Source: Accord Fintech
2024-03-11 01:45:18 pm
Zydus Lifesciences trades higher on the BSE Zydus Lifesciences is currently trading at Rs. 1007.05, up by 30.25 points or 3.10% from its previous closing of Rs. 976.80 on the BSE. The scrip opened at Rs. 986.60 and has touched a high and low of Rs. 1015.70 and Rs. 980.00 respectively. So far 44133 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1015.70 on 11-Mar-2024 and a 52 week low of Rs. 461.50 on 13-Mar-2023. Last one week high and low of the scrip s...
Zydus Lifesciences trades higher on the BSE
Zydus Lifesciences trades higher on the BSE
Source: Accord Fintech
2024-03-11 11:22:30 am